Abstract
Previous investigations revealed that AB0 blood groups are associated with divergent concentrations of several coagulation factors. Concentrations of von Willebrand factor (vWF) and factor VIII are lower in individuals with blood group 0 compared to subjects with blood group A, B or AB, which might in turn result in a reduced inhibition of platelet aggregation in individuals with blood group 0. The aim of the present in vitro investigation was to elucidate the impact of AB0 blood group-dependent vWF concentrations on eptifibatide and abciximab mediated inhibition of GPIIb/IIIa function. Platelet function was measured with the platelet function analyzer PFA-100(R) at baseline and at increasing concentrations of eptifibatide and abciximab. It was stratified for blood group 0 vs A. If measured with the collagen/ADP cartridge, blood group 0 was associated with a prolonged mean baseline closure time in comparison with blood group A (94.3 +/- 14.6 s vs. 74.6 +/- 9.9 s, p = 0.007) which was paralleled by reduced concentrations of vWF and factor VIII. In contrast, no statistically significant differences in closure times (167.4 +/- 83.9 s vs. 140.1 +/- 99.0 s, p = 0.562) could be found in the presence of eptifibatide (0.1 microg/ml). H...Continue Reading
References
Jan 2, 1971·British Medical Journal·T C Northfield
Mar 1, 1966·British Journal of Haematology·C B KerrR Biggs
Oct 1, 1995·American Heart Journal·W H FrishmanK Lerrick
Dec 1, 1995·Journal of the American College of Cardiology·N S KleimanH F Weisman
Jan 1, 1995·Vox Sanguinis·M ShimaA Yoshioka
Apr 7, 1994·The New England Journal of Medicine·UNKNOWN EPIC Investigators
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
Jul 22, 1998·Lancet·UNKNOWN EPISTENT Investigators
Aug 15, 1998·The New England Journal of Medicine·UNKNOWN Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigato
Jan 29, 1999·Lancet·E J TopolE F Plow
Jun 5, 1999·The American Journal of Cardiology·J E Tcheng
Jan 29, 2000·American Heart Journal·J E Tcheng
Mar 23, 2000·Journal of Thrombosis and Thrombolysis·S R Steinhubl
Aug 11, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·J C SoutoJ Fontcuberta
Feb 13, 2001·Transfusion·A MoellerV Kretschmer